Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Spero Therapeutics, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Spero Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Spero Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is SPRO. The reporting company's CIK number is 1701108.
The total value of stock buying since 2005 is $21,090,972.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2017-11-06||Larkin Cristina (Chief Operating Officer)||Buy||1,500||14.00||21,000|
|2017-11-06||Goyal Vikas (Director)||Buy||428,571||14.00||5,999,994|
|2017-11-06||Sendek Joel (Chief Financial Officer)||Buy||5,000||14.00||70,000|
|2017-11-06||Breum Casper (Director)||Buy||214,285||14.00||2,999,990|
|2017-11-06||Formela Jean Francois (Director)||Buy||428,571||14.00||5,999,994|
Insider trading activities including stock purchases, stock sales, and option exercises of SPRO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Spero Therapeutics, Inc. (symbol SPRO, CIK number 1701108) see the Securities and Exchange Commission (SEC) website.